Deerfield Management Company, L.P. (Series C) Sangamo Therapeutics, Inc Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2017 Feb 14, 2018	SELL	$11.6 - $17.35 $7.57 Million - $11.3 Million	-653,000 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$8.4 - $15.0 $5.49 Million - $9.8 Million	653,000	653,000 $9.8 Million

Others Institutions Holding SGMO

# of Institutions

111

Shares Held

56.7M

Call Options Held

576K

Put Options Held

1.17M

Wasatch Advisors Inc Salt Lake City, UT

19.4M
Shares

$23.9 Million
0.08% of portfolio
Vanguard Group Inc Valley Forge, PA

9.6M
Shares

$11.8 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

4.85M
Shares

$5.97 Million
0.01% of portfolio
Black Rock Inc. New York, NY

4.7M
Shares

$5.78 Million
0.0% of portfolio
Marshall Wace, LLP London, X0

2.35M
Shares

$2.9 Million
0.0% of portfolio

View Full List

About SANGAMO THERAPEUTICS, INC

Ticker SGMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 156,552,992
Market Cap $193M
Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...

More about SGMO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account